Naturally, drug researchers like to tout their victories and downplay their failures. But there are ramifications of not reporting results of experiments that go poorly, and two academics recently took on the issue in an a Science Translational Medicine article that says "translational medicine cannot approach its full potential if negative drug developments are unpublished," as Pharmalot's Ed Silverman cited in his interview with one of the authors. Michael Rogawski, chair of the department of neurology at UC Davis School of Medicine, talks to Silverman about his efforts to get developers to publish data they might rather keep under wraps. Interview